Literature DB >> 11425500

Sequential regional cerebral blood flow brain scans using PET with H2(15)O demonstrate ketamine actions in CNS dynamically.

H H Holcomb1, A C Lahti, D R Medoff, M Weiler, C A Tamminga.   

Abstract

The aim of this study was to examine the potential of serial rCBF studies to directly characterize the regional effects and dynamic time course of the centrally active drug ketamine. The value of a broader application of this technique to other neurally active drugs to characterize the pharmacodynamics of CNS compounds is suggested by these data. Thirteen normal subjects received a 0.3 mg/kg intravenous dose of ketamine over 60 seconds; ten other individuals received placebo in the same manner. For each subject, three baseline PET rCBF scans and seven sequential post-ketamine scans at 10-minute intervals were obtained using H(2)(15)O water. SPM techniques were employed to identify the maxima of any cluster significant by spatial extent analysis at any post-ketamine time point between 0 and 36 min. These extremes from the ketamine group, were identified in placebo scans similarly and grown to a 6x6x12 mm voxel set. The average rCBF values of the ketamine-defined clusters were determined in the drug and placebo conditions at all time points. rCBF across time was plotted for each cluster and compared between drug and placebo. Area under the curve (AUC) was calculated between baseline and 36 minutes. The kinetic characteristics of the ketamine-induced rCBF curves were compared to induced behaviors in each maxima. Ketamine produced distinct patterns of rCBF change over time in different brain regions; maxima within an anatomically defined region responded similarly. Ketamine induced rCBF activations in anterior cingulate, medial frontal and inferior frontal cortices. All maxima with a relative flow reduction with ketamine were in the cerebellum. The pattern of all activations and suppressions was monophasic with the peak changes at 6-16 minutes. In preliminary analysis, individual C(max) and AUC of maxima in the anterior cingulate/medial frontal region tended to correlate with the mild psychotomimetic action of ketamine; whereas, there was no tendency toward correlation with this psychological change in cerebellar maxima. The direct action of a centrally active drug can be assessed regionally and dynamically in brain using rCBF and a scan sequence optimally timed to complement the drug's time course. Ketamine pharmacodynamic response can be related to concurrent behavioral changes, tending to link the behavior with a brain region. This experimental design provides direct characterization of drug action in the CNS in ways heretofore unavailable.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11425500     DOI: 10.1016/S0893-133X(01)00229-9

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  43 in total

1.  Phenomenologically distinct psychotomimetic effects of ketamine are associated with cerebral blood flow changes in functionally relevant cerebral foci: a continuous arterial spin labelling study.

Authors:  T A Pollak; S De Simoni; B Barimani; F O Zelaya; J M Stone; M A Mehta
Journal:  Psychopharmacology (Berl)       Date:  2015-10-05       Impact factor: 4.530

2.  Modulatory effects of ketamine, risperidone and lamotrigine on resting brain perfusion in healthy human subjects.

Authors:  Sergey Shcherbinin; Orla Doyle; Fernando O Zelaya; Sara de Simoni; Mitul A Mehta; Adam J Schwarz
Journal:  Psychopharmacology (Berl)       Date:  2015-07-31       Impact factor: 4.530

3.  Context-Specific Tolerance and Pharmacological Changes in the Infralimbic Cortex-Nucleus Accumbens Shell Pathway Evoked by Ketamine.

Authors:  Gleice Kelli Silva-Cardoso; Manoel Jorge Nobre
Journal:  Neurochem Res       Date:  2021-03-30       Impact factor: 3.996

Review 4.  Anatomical abnormalities of the anterior cingulate cortex in schizophrenia: bridging the gap between neuroimaging and neuropathology.

Authors:  Alex Fornito; Murat Yücel; Brian Dean; Stephen J Wood; Christos Pantelis
Journal:  Schizophr Bull       Date:  2008-04-23       Impact factor: 9.306

5.  Prefrontal function at presentation directly related to clinical outcome in people at ultrahigh risk of psychosis.

Authors:  P Fusar-Poli; M R Broome; P Matthiasson; J B Woolley; A Mechelli; L C Johns; P Tabraham; E Bramon; L Valmaggia; S C Williams; P McGuire
Journal:  Schizophr Bull       Date:  2009-08-07       Impact factor: 9.306

6.  "Resting" CBF in the epileptic baboon: correlation with ketamine dose and interictal epileptic discharges.

Authors:  C Akos Szabó; Shalini Narayana; Crystal Franklin; Koyle D Knape; M Duff Davis; Peter T Fox; M Michelle Leland; Jeff T Williams
Journal:  Epilepsy Res       Date:  2008-09-17       Impact factor: 3.045

Review 7.  The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia.

Authors:  Samuel M Cohen; Richard W Tsien; Donald C Goff; Michael M Halassa
Journal:  Schizophr Res       Date:  2015-01-09       Impact factor: 4.939

8.  Ketamine induced changes in regional cerebral blood flow, interregional connectivity patterns, and glutamate metabolism.

Authors:  James Edward Bryant; Michael Frölich; Steve Tran; Meredith Amanda Reid; Adrienne Carol Lahti; Nina Vanessa Kraguljac
Journal:  J Psychiatr Res       Date:  2019-07-27       Impact factor: 4.791

9.  Acute ketamine administration alters the brain responses to executive demands in a verbal working memory task: an FMRI study.

Authors:  R A E Honey; G D Honey; C O'Loughlin; S R Sharar; D Kumaran; E T Bullmore; D K Menon; T Donovan; V C Lupson; R Bisbrown-Chippendale; P C Fletcher
Journal:  Neuropsychopharmacology       Date:  2004-06       Impact factor: 7.853

10.  In vivo neurometabolic profiling to characterize the effects of social isolation and ketamine-induced NMDA antagonism: a rodent study at 7.0 T.

Authors:  Antonio Napolitano; Khalid Shah; Mirjam I Schubert; Veronica Porkess; Kevin C F Fone; Dorothee P Auer
Journal:  Schizophr Bull       Date:  2013-05-13       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.